



Investor Briefing

BWXT
BWX Technologies, Inc.

3Q23 results
reported November 1, 2023

Forward-Looking Statements Disclaimer



BWX Technologies, Inc. (“BWXT”) cautions that statements in this presentation that are forward-looking and provide other than historical information involve risks and uncertainties that may impact actual results and any future performance suggested in the forward-looking statements. The forward-looking statements in this presentation include, but are not limited to, statements relating to our 2023 and future strategic priorities, including U.S. Navy procurement, microreactors, advanced nuclear fuels, medical radioisotope industrialization, small modular reactor components, recent acquisitions and organic growth opportunities; statements related to backlog, to the extent they may be viewed as an indicator of future revenues; the expected U.S. Navy long-term procurement schedules and forecasts; estimated pension costs; expected future capital expenditure levels; the expected Canadian nuclear power forecast for services, refurbishment timelines and opportunities; disruptions to our supply chain and/or operations, changes in government regulations and other factors; our outlook, priorities and growth opportunities in our businesses; and guidance for 2023 and beyond. These forward-looking statements are based on current management expectations and involve a number of risks and uncertainties, including, among other things, federal budget uncertainty, the risk of future budget cuts, the impact of continuing resolution funding mechanisms and the debt ceiling, the potential for government shutdowns and changing funding and acquisition priorities; our ability to win new project awards; the receipt and/or timing of government approvals; capital spending of power generating utilities; the timing of technology development, regulatory approvals and automation of production; the potential recurrence or subsequent waves or strains of COVID-19 or similar diseases; the actions to contain the impact of such diseases and potential employee unrest; adverse changes in the industries in which we operate; labor market challenges, including employee retention and recruitment; termination, delays and other difficulties executing on contracts in backlog and adverse changes in the demand for or competitiveness of nuclear products and services. If one or more of these or other risks materialize, actual results may vary materially from those expressed. For a more complete discussion of these and other risks, please see BWXT’s filings with the Securities and Exchange Commission, including our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. BWXT cautions not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation, and undertakes no obligation to update or revise any forward-looking statement, except to the extent required by applicable law.

BWX Technologies, Inc.
is using **nuclear technology**
to solve some of the world's
most important problems.

OUR MISSION:

We provide safe and effective solutions for global security, clean energy, environmental restoration, nuclear medicine and space exploration.

We maintain a commitment to innovation, operational excellence, safety and the highest ESG standards.

>\$2.4B

up high-single digits Y/Y

Estimated 2023 Revenue

~\$475M

up high-single digits Y/Y

Estimated 2023 Adj.
EBITDA⁽¹⁾

~\$200M

Estimated 2023
Free Cash Flow⁽¹⁾

>7,000

Employees

(1) Non-GAAP figures exclude any mark-to-market adjustment for pension and postretirement benefits recognized and other one-time items. A reconciliation and definition of GAAP to adjusted, non-GAAP items can be found in the Appendix section of this presentation. 2023 estimates based on guidance provided as of November 1, 2023.



Unique differentiators in specialized markets create favorable business characteristics

Unparalleled assets and strong market positioning across the portfolio

DECADES

of nuclear operation
experience

WORLD CLASS

nuclear manufacturing
facilities

ONLY

company to possess NRC
Category 1 licenses

SOLE SOURCE

position on mission-
critical programs



Distinct strategies for government and commercial markets



GOVERNMENT

Global security



- U.S. naval nuclear propulsion components
- U.S. Navy fuel manufacturing
- Highly engineered proprietary components for U.S. and U.K. submarine fleet

Nuclear fuels & uranium processing



- TRISO and coated nuclear fuel manufacturing
- Uranium conversion and purification services
- Research and test reactor fuel production
- Uranium recovery
- Uranium medical target manufacturing

Technical services



- Nuclear environmental restoration for U.S. Department of Energy (DOE) sites
- DOE site management and operation services

Advanced technologies



- Defense and space nuclear reactors
- Advanced reactor and fuel design
- Cutting-edge R&D

COMMERCIAL

Clean energy



- Nuclear component engineering and manufacturing
- Fuel manufacturing and fuel handling
- Nuclear spent fuel and waste containers
- Inspection, maintenance and field services

Nuclear medicine




- Diagnostic and therapeutic nuclear radiochemical manufacturing
- Generic radiopharmaceuticals
- Contract drug manufacturing



- 1 Transition to maintenance capital and fund incremental growth**
- 2 Focus on continuous improvement to hone the business**
- 3 Deliver on commitments for naval reactors and leverage unique capabilities to grow in other government nuclear markets**
- 4 Execute nuclear medicine commercialization strategy and position for next generation commercial nuclear power**
- 5 Achieve medium-term financial targets**



Heightened capex returning to normalized levels



Major growth capital campaigns (2017 – 2022)

- ### Naval reactors (~\$300M+)
- Maintaining 2 Virginia-class annual ordering cadence
 - Decadal growth of Columbia-class program
 - Accelerated carrier procurements
 - Provides some capacity for 3rd VA / AUKUS scenarios

- ### Medical radioisotopes (~\$300M+)
- Developing and constructing first-of-a-kind commercial Tc-99m generator production line
 - Includes facility modifications, reactor access equipment, radiochemistry and radiopharmacy investments

Select Growth Investments (2023+)


- Microreactors (PELE, DRACO), SMRs
- Small modular reactors / commercial nuclear
- Select therapeutic capabilities
- New Government programs

1) Based on assumptions for free cash flow guidance provided on November 1, 2023. For more information refer to the quarterly earnings and related material found on the BWXT investor relations website




Consolidate operating segments

- Effectively meet customer needs
- Drive future strategic and cost synergies for customers and shareholders



Increase operational effectiveness and modernize support functions

- Small investments in integrated business systems
- Digital transformation



Streamline financial execution

- Manage downward glide path on capex
- Improve managed working capital efficiency
- Realize margin expansion through cost efficiencies



3 Deliver on commitments for naval reactors and...



Government Fiscal Year ⁽¹⁾	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	
Aircraft Carrier Plan⁽²⁾																																
CVN (Ford Class)																																
Alternative 1						1				1					1					1						1					1	
Alternative 2						1				1					1					1						1					1	
Alternative 3						1				1				1					1				1				1				1	
Submarine Program⁽²⁾																																
SSN (Virginia / X-Class)	2	2	2	2	2																											
Alternative 1						2	2	1	1	2	1	2	1	2	2	2	2	2	1	2	2	2	2	2	1	2	2	2	2	2	2	
Alternative 2						2	2	2	2	2	1	2	2	3	2	3	2	2	3	3	2	2	3	2	2	3	2	2	3	2	2	
Alternative 3						2	2	1	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
SSBN (Columbia / X-Class)																																
	1				1	1																										
Alternative 1						1	1	1	1	1	1	1	1						1				1			1					1	
Alternative 2						1	1	1	1	1	1	1	1		1				1				1			1					1	
Alternative 3						1	1	1	1	1	1	1	1		1				1				1			1					1	


Solid, long-term visibility on future orders


BWXT orders ~2 years in advance of ship procurements


Individual years may be lumpy due to carrier activity

1) Source: Office of the Chief of Naval Operations report to Congress on the Annual Long-Range Plan for Construction of Naval Vessels for Fiscal Year 2024, published April 2023. Green and red shading indicate respective positive and negative change from prior shipbuilding plans/BWXT estimates.
2) Navy construction plan and order schedule may not directly align with ~2 year advance to BWXT calendar year.

3 ...leverage unique capabilities to grow in government special materials



Nuclear fuels



Research and test reactors



TRISO and other coated fuels

20%+
High enriched uranium
Category 1 license, only handlers are government & BWXT

5% - 19.99%
High-assay low-enriched uranium
Category 2 license high enriched fuels (TRISO)

0% - 4.99%
Low enriched uranium
Category 3 license

Uranium/Special Materials Processing



Downblending highly enriched uranium




Uranium conversion and purification

3 ...leverage unique capabilities to grow in government nuclear markets



Technical services market



Relative size and scale

- 10 of 33 DOE sites
- ~3600 employees
- ~\$1B unconsolidated revenue

Upcoming opportunities

(estimated annual budgets)

	Savannah River Site Integrated Mission Completion Contract	\$1-1.4B	~\$45M
		Won	
	Hanford Integrated Tank Disposition Contract ¹⁾	~\$2B	~\$55M
	Pantex M&O	~\$900M	~\$25M
	Portsmouth / Paducah Operations and Site Mission Support	~\$250M	~\$10M

= potential JV annual income opportunity

1) Under Department of Energy review as of the date of this presentation.

3 ...leverage unique capabilities to grow in government nuclear markets



BWXT positioning for wins across advanced nuclear microreactor programs

Off-grid and remote military applications



Space propulsion
Space power




National security space



Other applications



Potential # of units Likelihood of production



4 Execute nuclear medicine commercialization strategy...




Leverage BWXT's differentiated technology and capabilities




Current supply dynamics



Complex supply chain



BWXT supply dynamics



Lower Cost

More Reliable

Drop-in Replacement


4 Execute nuclear medicine commercialization strategy...



Opportunity and progress on BWXT's Tc-99m generator project

\$400M - \$500M⁽¹⁾ annual global Mo-99 / Tc-99m generator segment

Major milestones



North America

Become supplier to leading nuclear medicine companies

Asia

BWXT / GMS joint venture

Europe

TBA

- ✓ FDA, BWXT Type C meeting
- ✓ Design reactor access equipment
- ✓ Design manufacturing and processing equipment
- ✓ Manufacture reactor access equipment
- ✓ Install final manufacturing equipment
- ✓ Modify medical radioisotope facility
- ✓ Run equipment validations
- ✓ Submit application to FDA
- ✓ Install CANDU reactor access equipment
- FDA approval for BWXT Tc-99m generator

✓ = completed

1) BWXT estimate



Examples of BWXT emerging as a preferred partner

Build upon existing products

Long-term, mutually exclusive agreement to manufacture TheraSphere

- Current therapeutic product developed for the treatment of liver cancer
- Growing global demand driven by 2021 FDA approval – expanding patient access
- Investing to automate production process to significantly increase capacity to meet demand

Boston Scientific



Create to capture – leverage partners

Collaboration with Bayer AG and Fusion Pharmaceuticals for Actinium-225 supply

- Used in targeted alpha therapies for various tumors
- BWXT intends to leverage isotope and CDMO capabilities to manufacture finished drugs



Development of Lutetium-177 supply

- Used in targeted beta therapies for various tumors
- BWXT intends to leverage relationships with strategic partners for irradiation services



Government

U.S. budgets

High-Assay Low-Enriched Uranium

\$800M

Office of Nuclear Energy

\$1.8B

DOE Advanced Reactor Demonstration Program

\$2.4B

Canada

10+

Advanced reactors in licensing process

\$970M CAD

Secured funding from Canadian Infrastructure Bank for first grid-scale SMR

ONTARIOPOWER
GENERATION

OPG targeting a grid-connected SMR by 2028

Private industry



Bill Gates founded / funded Sodium reactor

Warren Buffet's PacifiCorp - initial site and purchaser of advanced reactor at retiring coal plant in Wyoming



Developing Xe-100



Evaluating advanced nuclear solutions for mining operations



HITACHI

BWRX-300; signs agreements for potential new builds in various countries



CROWLEY

Exploring a ship concept to deliver back-up and relief power



TERRESTRIAL
ENERGY



BWXT positioned to capture manufacturing opportunities in next-generation commercial nuclear power build-out

5 Achieve medium-term financial targets



Mid-to-high-single digit adj. EBITDA⁽¹⁾ growth

- Sustained revenue growth; all segments
- Margin expansion outside of Navy business




>85% FCF⁽¹⁾ conversion

- Modest improvements in working capital as % sales
- Maintenance capex run-rate exiting 2022



>50% FCF⁽¹⁾ return to shareholders

- **Dividend:** In line with historical ratio to earnings;
- **Share repurchases:** remaining balance of >50% FCF⁽¹⁾ allocation target, pending market conditions
- Other cash / debt could be invested in organic / inorganic growth opportunities with attractive returns



1) Non-GAAP figures exclude any mark-to-market adjustment for pension and postretirement benefits recognized and other one-time items. A reconciliation and definitions of GAAP to adjusted, non-GAAP items can be found in the Appendix section of this presentation.

5 Achieve medium-term financial targets



Multiple levers to drive mid-to-high single digit adjusted EBITDA⁽¹⁾ growth

Underlying market growth

2.5 to 4.0%

Incremental growth vectors

2.0 to 4.0%



Operational efficiency initiatives

~0.5%

Mid-to-high single digit growth


  Columbia growth

  Aircraft carrier gap years

  FAS/CAS pension roll-off

  High fixed infrastructure dynamic

  Clean energy growth

  Nuclear medicine base growth

  New nuclear medicine products

  Nuclear medicine start-up costs

  Increased DOE services wins

  Defense and Space reactor prototypes

  New nuclear fuels

  Digital transformation

  BWXT business system

  Software transition costs

Executing and streamlining while investing and expanding into nuclear adjacencies provides an attractive growth profile


1) Non-GAAP figures exclude any mark-to-market adjustment for pension and postretirement benefits recognized and other one-time items. A reconciliation and definitions of GAAP to adjusted, non-GAAP items can be found in the Appendix section of this presentation.

5 Achieve medium-term financial targets



Continue strong operating cash flow generation and align capital to priority framework

Historical adjusted operating cash flow⁽¹⁾



Future capital allocation priority framework

- 1 Complete two major growth capital campaigns
- 2 Fund incremental capital in nuclear adjacencies:
 - Microreactor and SMR manufacturing capacity
 - Advanced capabilities in nuclear medicine
 - Advanced nuclear fuels
- 3 Greater return to shareholders **>50%** FCF return
- 4 Potential acquisitions


1) Adjusted operating cash flow = operating cash flow less net cash used for discretionary pension contributions, excluding any related tax impacts and other one-time items. 2017 adjustments include a \$30 million discretionary pension contribution and 2018 adjustments include \$118 million in discretionary pension contributions. 2020 and 2021 adjustment includes an \$89 million late payment from customer received January 4, 2021. Shaded areas include add back to reported figures. Dashed areas are subtraction from reported figures.



Segment details



Government Operations



Key takeaways


- Decades of high consequence nuclear operations experience
- Sole provider of U.S. Navy nuclear propulsion components and fuel
- Only company to possess Category 1 nuclear credentials
- Differentiated capabilities in emerging nuclear microreactor market
- Leadership position maintained through safety, quality and performance track record

Outlook and growth opportunities

- Long-term growth in nuclear navy production primarily driven by Columbia ballistic missile submarine
- Opportunities to leverage category I credentials to expand strategic material production/services
- Poised for market share gains in DOE nuclear technical services
- Positioning for more wins across advanced nuclear microreactor programs



Global security



Nuclear fuels & uranium processing





Technical services



Advanced technologies

1) 2023 guidance as of November 1, 2023. For more information refer to the quarterly earnings and related material found on the BWXT investor relations website

Critical aspects of naval nuclear propulsion



1) Engine room components in red produced by BWXT

BWXT / Naval reactors contracts overview



2 or 3-year
order pricing agreements




6+ year
contract timeline

Fixed price incentive fee

~15% as-sold fee on cost



Margins increase
as savings are realized over time

Cost underruns shared with customer, boost margins



*For illustrative purposes only

Commercial Operations



Key takeaways

- Unique strengths, capabilities and market position in nuclear power, a clean energy source essential to meet net-zero carbon objectives
- Long-term demand driven by Canadian life-extension projects
- Positioned to capture advanced reactor supplier opportunities
- Strong nuclear medicine market growth driven by therapeutics
- BWXT technology addresses market challenges and future needs
- Aim to become a leading nuclear medicine manufacturing company and at an inflection point to generate significant shareholder value

Outlook and growth opportunities

- Commercial power recurring work provides long-term visibility and life-extension projects establish stable medium-term volume
- Opportunities for growth with small modular and advanced reactors; Canada ordering first, four small modular reactors, other utilities pursuing
- Potential for new large reactors at existing sites
- Market growth with current medical radioisotope portfolio
- Entry into Tc-99m market anticipated to accelerate growth
- Emerging demand for therapeutic radioisotopes and market need for contract drug manufacturing

1) 2023 guidance as of November 1, 2023. For more information refer to the quarterly earnings and related material found on the BWXT investor relations website

How BWXT serves the CANDU commercial nuclear power fleet



Recurring



Services




Fuel / spent fuel containers



Components



- Components/Engineering
- Fuel & Fuel Handling
- Outage & Field Services



Life extension



Waste containers




Components



Services

10 reactors being refurbished

Non-recurring life extension market**



Emerging Opportunities (relative scale for BWXT)

Pickering life extensions through 2026



Longer-term Pickering life extensions



Large-scale new CANDU reactor builds



Near-Term

Medium-Term

Longer-Term

**Source: Based on BWXT estimates

Uniquely positioned between pharma and traditional nuclear medicine



Irradiation process

Nuclear medicine manufacturing

Drug development and distribution

Nuclear reactors



Cyclotrons



Isotope processing & production



Radiopharmaceutical & contract drug manufacturing



Drug development



Radiopharmacies



Hospitals, physicians, technologists, patients

Global nuclear medicine market

Share of selling price

One-Third of selling price

Two-Thirds of selling price

Financial risk

Low to Medium

High

Expectations for BWXT's nuclear medicine manufacturing business⁽¹⁾



	R&D & acquire to accelerate	Tc-99m construction	Commercialize and ramp	Grow into global leader
	2017 - 2018	2019 - 2021	2022 - 2024	2025+
Milestones	<ul style="list-style-type: none"> Tc-99m innovation Acquire facility / personnel 	<ul style="list-style-type: none"> Construct Tc-99m product line Expand to 7 active products 	<ul style="list-style-type: none"> Tc-99m FDA approval Expand therapeutic strategy 	<ul style="list-style-type: none"> 10+ products including therapeutic radioisotopes and finished drug manufacturing
Investment	\$213M acquisition	~\$300M capex	Modest	Modest
Sales	\$45M acquired	\$50M+ enhanced	~\$60M → ~\$125M inflecting	\$200M+ continued growth
Tc-99m Start-up Costs	Minimal	(\$15M)-(\$20M) per annum	~(\$20M) per annum	
Total BWXT Medical EBITDA	\$13M	(\$5M)-(\$10M) per annum	~(\$10M) → \$25M+	\$75M+
D&A		~\$6M Nordion amortization per annum		~\$20M Tc-99m D&A per annum (upon commercialization)
Value Creation	<p>Innovative Tc-99m IP option + Acquired Business</p>	<p>Enhanced business + Tc-99m NPV + therapeutic option</p>	<p>Tc-99m and therapeutic portfolio begins generating meaningful profit</p>	<p>Significant value inside BWXT of a global nuclear medical manufacturing platform</p>

1) unaudited, pro forma consolidated figures as reported at BWXT Investor Day on November 16, 2021



Latest results and guidance

3Q23

Third Quarter 2023 and Outlook Highlights







- **3Q23 Y/Y financial performance**
 - Revenue **up 13%**, adjusted EBITDA⁽¹⁾ **up 6%**, and FCF⁽¹⁾ **up \$18M**.
 - Strong organic revenue growth in Government Operations and Commercial Operations
 - EBITDA growth driven by CO margin expansion, including improved medical profitability, and slightly lower GO margins as solid underlying performance was offset by expected onboarding inefficiencies and program mix
- **Nuclear playing a major role for Government and Commercial Clients**
 - **Global Security:** Government support for long-term shipbuilding plan, AUKUS trilateral security agreement (Australia investment in U.S. industrial base); Negotiating next multi-year pricing agreement
 - **Advanced Technologies:** DARPA DRACO contract for space nuclear propulsion demonstration; Wyoming Energy Authority and Crowley exploring microreactors for commercial applications
 - **Clean Energy:** Growing global support for new nuclear investment; Addressing calls for large-scale greenfield CANDU plants (Canada and other international markets); Pickering life extensions; SMR opportunities
 - **BWXT Medical:** Radiopharmaceutical pipeline continuing to expand; Continued growth of diagnostics business; Tc-99m commercialization expected in 2024
- **2023 Non-GAAP⁽¹⁾ EPS guidance narrowed to \$2.90-\$2.95**
- **Expect mid-single-digits earnings growth in 2024 driven by organic revenue growth and solid execution**
 - Mid-single-digit revenue growth: Growth in both segments, led by Commercial
 - Higher Commercial margin offset by slightly lower Government margin
 - 2024 Free Cash Flow⁽¹⁾ growth expected to exceed adjusted EBITDA⁽¹⁾ growth

(1) Non-GAAP figures exclude any mark-to-market adjustment for pension and postretirement benefits recognized and other one-time items. A reconciliation of GAAP to adjusted, non-GAAP items can be found in the Appendix section of this presentation.

3Q23 financial summary



(\$million, except per share amounts)




- 3Q23 revenue up 13% from higher revenue in Government Operations and Commercial Operations
- 3Q23 adj. EBITDA⁽¹⁾ up 6% as higher revenue was partially offset by lower margin due to product mix in Government and higher corporate costs, mitigated by higher Commercial margin, driven by Medical profitability
- 3Q23 non-GAAP⁽¹⁾ EPS down 3% as higher operating income was offset by higher interest expense and lower pension income
- 3Q23 OCF increased driven by better working capital management. 3Q23 FCF⁽¹⁾ was \$43M, an \$18M year-over-year improvement, driven by OCF improvement and slightly lower capital expenditures
 - Capital expenditures down Y/Y driven by timing of two major capital campaigns nearing completion, partially offset by increases in other growth capital

(1) Non-GAAP figures exclude any mark-to-market adjustment for pension and postretirement benefits recognized and other one-time items. A reconciliation and definition of GAAP to adjusted, non-GAAP items can be found in the Appendix section of this presentation.

3Q22 to 3Q23 non-GAAP⁽¹⁾ EPS bridge



(\$ per diluted share)



Operations

Pension/Other
Income

Interest Expense, Net

Tax Rate

3Q23

(1) Non-GAAP figures exclude any mark-to-market adjustment for pension and postretirement benefits recognized and other one-time items. A reconciliation of GAAP to adjusted, non-GAAP items can be found in the Appendix section of this presentation.

(2) Items may not foot due to rounding.


3Q23 segment summary



Government Operations


(\$million)

Revenue



3Q23 revenue up 13% from higher volume of naval nuclear component manufacturing, microreactor design activities, and uranium processing, partially offset by lower long-lead material procurement


Operating income & Adj. EBITDA⁽¹⁾ / margin



3Q23 adj. EBITDA⁽¹⁾ up 10% from higher revenue mitigated by onboarding inefficiencies, and less favorable mix, due to project timing and slightly lower technical services joint venture income


Commercial Operations

Revenue



3Q23 revenue up 10% from higher commercial nuclear field services, and higher BWXT Medical sales, partially offset by lower fuel handling volume

Operating income & Adj. EBITDA⁽¹⁾ / margin




3Q23 adj. EBITDA⁽¹⁾ up 22% from better profitability in BWXT Medical, mitigated by less favorable business mix in commercial nuclear that was skewed towards refurbishment projects

(1) Non-GAAP figures exclude any mark-to-market adjustment for pension and postretirement benefits recognized and other one-time items. A reconciliation of GAAP to adjusted, non-GAAP items can be found in the Appendix section of this presentation.

2022 to 2023 non-GAAP⁽¹⁾ EPS bridge



(\$ per diluted share)



(1) Non-GAAP figures exclude any mark-to-market adjustment for pension and postretirement benefits recognized and other one-time items. A reconciliation of GAAP to adjusted, non-GAAP items can be found in the Appendix section of this presentation.

Narrowing 2023 Guidance; Preliminary 2024 Outlook



Organic Revenue Growth and Solid Execution Expected to Lead to Mid-Single-Digit Earnings Growth in 2024

	2023 Guidance	Preliminary 2024 Outlook ⁽²⁾
Revenue	<p>>\$2.4B <i>Up high-single digits</i></p>	<ul style="list-style-type: none"> ○ Mid-single digit revenue growth <ul style="list-style-type: none"> ○ GO growth: slightly higher (non-naval growth mitigated by naval ordering cadence) ○ CO growth: higher (robust medical growth and building commercial power momentum)
Adj. EBITDA⁽¹⁾	<p>~\$475M <i>up high-single digits ~20% EBITDA margin</i></p>	<ul style="list-style-type: none"> ○ Mid-single-digit Adjusted EBITDA⁽¹⁾ and Non-GAAP EPS⁽¹⁾ growth <ul style="list-style-type: none"> ○ Operational: <ul style="list-style-type: none"> ○ GO margin: slightly lower (solid underlying performance, offset by program mix and non-recurring recovery benefit in 2023) ○ CO margin: higher (medical mix and steady commercial power) ○ Corporate EBITDA expense flattening out ○ Non-Operational: <ul style="list-style-type: none"> ○ Pension income (in other income) and interest expense combined are flat year-over-year ○ Consistent tax rate
Non-GAAP EPS⁽¹⁾	<p>\$2.90 - \$2.95 <i>down ~7%</i></p>	
Free Cash Flow⁽¹⁾	<p>~\$200M <i>significant inflection up</i></p>	<ul style="list-style-type: none"> ○ Free Cash Flow⁽¹⁾ to exceed Adjusted EBITDA⁽¹⁾ growth <ul style="list-style-type: none"> ○ OCF: higher (profit growth and improved working capital) ○ Capex: maintenance capex discipline plus growth investment (microreactors, therapeutics, SMR's)

(1) Adjusted Pre-tax income and Non-GAAP EPS exclude any mark-to-market adjustment for pension and postretirement benefits recognized and other one-time items, which are not known at the time guidance is provided. A reconciliation of GAAP to adjusted, non-GAAP items can be found in the Appendix section of this presentation.

(2) 2023 growth rates compared to 2022; 2024 growth rates based on mid-point of 2023 guidance



Appendix

Pension summary and non-GAAP reconciliations

Pension summary



<i>(\$millions)</i>	2018	2019	2020	2021	2022	2023E
Benefit obligation at end of period	1,186	1,309	1,414	1,308	927	
Fair value of plan assets at end of period	1,024	1,150	1,281	1,257	876	
Funded status over (under)	(162)	(158)	(133)	(51)	(51)	
% Funded	86%	88%	91%	96%	94%	
Pension funding (company contributions)	158	4	5	6	14	~5
Reported in other income						
Net periodic benefit cost (income)	6	(11)	(30)	(86)	3	
Recognized net actuarial Mark-To-Market (MTM) loss	37	9	7	(35)	52	
Net periodic benefit cost (income) excl. MTM loss	(31)	(21)	(37)	(52)	(49)	~(10)
Reported in operating income						
Recoverable CAS ⁽¹⁾ costs	44	47	44	29	12	
FAS ⁽²⁾ service cost	10	9	11	12	11	
Total FAS⁽²⁾/CAS⁽¹⁾ differential	34	38	33	17	1	~5

1) CAS – Cost accounting standards in accordance with the Federal Acquisition Regulation and the related U.S. Government Cost Accounting Standards – used as basis for recovery of costs on government contracts

2) FAS – Financial accounting standards in accordance with GAAP and the way we report our financial results



Non-GAAP figures exclude any mark-to-market adjustment for pension and postretirement benefits recognized and other one-time items.

Other non-GAAP definitions and calculations

Adjusted EBITDA = *Earnings Before Interest, Taxes, Depreciation and Amortization. Calculated using non-GAAP Net income, plus Provision for Income Taxes, less Other – net, less Interest income, plus Interest expense, plus Depreciation and amortization.*

FCF = *Free Cash Flow. Calculated using net income to derive Net Cash Provided By (Used In) Operating Activities less Purchases of property, plant and equipment.*

FCF Conversion = *Free Cash Flow Conversion. Free Cash Flow divided by net income*

3Q 2023 non-GAAP reconciliations



BWX TECHNOLOGIES, INC.

RECONCILIATION OF NON-GAAP OPERATING INCOME AND EARNINGS PER SHARE⁽¹⁾⁽²⁾⁽³⁾

(In millions, except per share amounts)

Three Months Ended September 30, 2023

	GAAP	Restructuring & Transformation Costs	Acquisition-related Costs	Non-GAAP
Operating Income	\$ 85.4	\$ 1.1	\$ 0.3	\$ 86.7
Other Income (Expense)	(7.2)	—	—	(7.2)
Income Before Provision for Income Taxes	78.2	1.1	0.3	79.5
Provision for Income Taxes	(17.8)	(0.1)	(0.1)	(18.0)
Net Income	60.4	1.0	0.2	61.5
Net Income Attributable to Noncontrolling Interest	(0.1)	—	—	(0.1)
Net Income Attributable to BWXT	\$ 60.3	\$ 1.0	\$ 0.2	\$ 61.5
Diluted Shares Outstanding	91.9			91.9
Diluted Earnings per Common Share	\$ 0.66	\$ 0.01	\$ 0.00	\$ 0.67
Effective Tax Rate	22.8%			22.6%
Government Operations Operating Income	\$ 85.6	\$ —	\$ —	\$ 85.6
Commercial Operations Operating Income	\$ 9.1	\$ 0.1	\$ 0.1	\$ 9.4
Unallocated Corporate Operating Income	\$ (9.4)	\$ 1.0	\$ 0.1	\$ (8.3)

RECONCILIATION OF CONSOLIDATED ADJUSTED EBITDA⁽¹⁾⁽²⁾⁽³⁾

(In millions)

Three Months Ended September 30, 2023

	GAAP	Restructuring & Transformation Costs	Acquisition-related Costs	Non-GAAP
Net Income	\$ 60.4	\$ 1.0	\$ 0.2	\$ 61.5
Provision for Income Taxes	17.8	0.1	0.1	18.0
Other – net	(4.3)	—	—	(4.3)
Interest Expense	12.2	—	—	12.2
Interest Income	(0.6)	—	—	(0.6)
Depreciation & Amortization	19.8	—	—	19.8
Adjusted EBITDA	\$ 105.2	\$ 1.1	\$ 0.3	\$ 106.5

RECONCILIATION OF REPORTING SEGMENT ADJUSTED EBITDA⁽¹⁾⁽²⁾⁽³⁾

(In millions)

Three Months Ended September 30, 2023

	Operating Income (GAAP)	Non-GAAP Adjustments ⁽⁴⁾	Depreciation & Amortization	Adjusted EBITDA
Government Operations	\$ 85.6	\$ —	\$ 13.4	\$ 99.0
Commercial Operations	\$ 9.1	\$ 0.3	\$ 4.6	\$ 13.9

RECONCILIATION OF CONSOLIDATED FREE CASH FLOW⁽¹⁾⁽²⁾⁽³⁾

(In millions)

Three Months Ended September 30, 2023

Net Cash Provided By Operating Activities	\$ 74.3
Purchases of Property, Plant and Equipment	(30.9)
Free Cash Flow	\$ 43.4

- (1) Tables may not foot due to rounding.
- (2) BWXT is providing non-GAAP information regarding certain of its historical results and guidance on future earnings per share to supplement the results provided in accordance with GAAP and it should not be considered superior to, or as a substitute for, the comparable GAAP measures. BWXT believes the non-GAAP measures provide meaningful insight and transparency into the Company's operational performance and provides these measures to investors to help facilitate comparisons of operating results with prior periods and to assist them in understanding BWXT's ongoing operations.
- (3) BWXT has not included a reconciliation of provided non-GAAP guidance to the comparable GAAP measures due to the difficulty of estimating any mark-to-market adjustments for pension and post-retirement benefits, which are determined at the end of the year.
- (4) For Non-GAAP adjustment details, see reconciliation of non-GAAP operating income and earnings per share.

3Q 2022 non-GAAP reconciliations



BWX TECHNOLOGIES, INC.

RECONCILIATION OF NON-GAAP OPERATING INCOME AND EARNINGS PER SHARE⁽¹⁾⁽²⁾⁽³⁾

(In millions, except per share amounts)

Three Months Ended September 30, 2022

	GAAP	Restructuring Costs	Acquisition-related Costs	Non-GAAP
Operating Income	\$ 79.9	\$ 1.2	\$ 0.5	\$ 81.5
Other Income (Expense)	2.1	—	—	2.1
Income Before Provision for Income Taxes	82.0	1.2	0.5	83.7
Provision for Income Taxes	(20.2)	(0.2)	(0.1)	(20.5)
Net Income	61.8	1.0	0.4	63.2
Net Income Attributable to Noncontrolling Interest	(0.2)	—	—	(0.2)
Net Income Attributable to BWXT	\$ 61.6	\$ 1.0	\$ 0.4	\$ 63.0
Diluted Shares Outstanding	91.7			91.7
Diluted Earnings per Common Share	\$ 0.67	\$ 0.01	\$ 0.00	\$ 0.69
Effective Tax Rate	24.6%			24.5%
Government Operations Operating Income	\$ 77.7	\$ —	\$ 0.5	\$ 78.2
Commercial Operations Operating Income	\$ 6.8	\$ —	\$ —	\$ 6.8
Unallocated Corporate Operating Income	\$ (4.7)	\$ 1.2	\$ —	\$ (3.5)

RECONCILIATION OF CONSOLIDATED ADJUSTED EBITDA⁽¹⁾⁽²⁾⁽³⁾

(In millions)

Three Months Ended September 30, 2022

	GAAP	Restructuring Costs	Acquisition-related Costs	Non-GAAP
Net Income	\$ 61.8	\$ 1.0	\$ 0.4	\$ 63.2
Provision for Income Taxes	20.2	0.2	0.1	20.5
Other – net	(11.5)	—	—	(11.5)
Interest Expense	9.6	—	—	9.6
Interest Income	(0.3)	—	—	(0.3)
Depreciation & Amortization	18.6	—	—	18.6
Adjusted EBITDA	\$ 98.5	\$ 1.2	\$ 0.5	\$ 100.1

RECONCILIATION OF REPORTING SEGMENT ADJUSTED EBITDA⁽¹⁾⁽²⁾⁽³⁾

(In millions)

Three Months Ended September 30, 2022

	Operating Income (GAAP)	Non-GAAP Adjustments ⁽⁴⁾	Depreciation & Amortization	Adjusted EBITDA
Government Operations	\$ 77.7	\$ 0.5	\$ 12.1	\$ 90.4
Commercial Operations	\$ 6.8	\$ —	\$ 4.6	\$ 11.5

RECONCILIATION OF CONSOLIDATED FREE CASH FLOW⁽¹⁾⁽²⁾⁽³⁾

(In millions)

Three Months Ended September 30, 2022

Net Cash Provided By Operating Activities	\$ 65.0
Purchases of Property, Plant and Equipment	(39.6)
Free Cash Flow	\$ 25.4

- (1) Tables may not foot due to rounding.
- (2) BWXT is providing non-GAAP information regarding certain of its historical results and guidance on future earnings per share to supplement the results provided in accordance with GAAP and it should not be considered superior to, or as a substitute for, the comparable GAAP measures. BWXT believes the non-GAAP measures provide meaningful insight and transparency into the Company's operational performance and provides these measures to investors to help facilitate comparisons of operating results with prior periods and to assist them in understanding BWXT's ongoing operations.
- (3) BWXT has not included a reconciliation of provided non-GAAP guidance to the comparable GAAP measures due to the difficulty of estimating any mark-to-market adjustments for pension and post-retirement benefits, which are determined at the end of the year.
- (4) For Non-GAAP adjustment details, see reconciliation of non-GAAP operating income and earnings per share.

2022 non-GAAP reconciliations



BWXT TECHNOLOGIES, INC. RECONCILIATION OF NON-GAAP OPERATING INCOME AND EARNINGS PER SHARE⁽¹⁾⁽²⁾⁽³⁾ (In millions, except per share amounts)

	Year Ended December 31, 2022						Non-GAAP
	GAAP	Pension & OPEB MTM (Gain) / Loss	Restructuring Costs	Acquisition-related Costs	Loss on Asset Disposal		
Operating Income	\$ 348.6	\$ —	\$ 8.2	\$ 2.6	\$ 6.2	\$ 365.6	
Other Income (Expense)	(34.2)	46.6	0.0	—	—	12.4	
Income before Provision for Income Taxes	314.4	46.6	8.2	2.6	6.2	378.0	
Provision for Income Taxes	(75.8)	(10.9)	(1.9)	(0.4)	(1.6)	(90.5)	
Net Income	238.6	35.7	6.3	2.2	4.7	287.5	
Net Income Attributable to Noncontrolling Interest	(0.4)	—	—	—	—	(0.4)	
Net Income Attributable to BWXT	\$ 238.2	\$ 35.7	\$ 6.3	\$ 2.2	\$ 4.7	\$ 287.1	
Diluted Shares Outstanding	91.7					91.7	
Diluted Earnings per Common Share	\$ 2.60	\$ 0.39	\$ 0.07	\$ 0.02	\$ 0.05	\$ 3.13	
Effective Tax Rate	24.1%					23.9%	
Government Operations Operating Income	\$ 336.5	\$ —	\$ 1.2	\$ 0.8	\$ —	\$ 338.6	
Commercial Operations Operating Income	\$ 27.4	\$ —	\$ 1.5	\$ —	\$ 6.2	\$ 35.1	
Unallocated Corporate Operating Income	\$ (15.3)	\$ —	\$ 5.4	\$ 1.8	\$ —	\$ (8.1)	

RECONCILIATION OF CONSOLIDATED ADJUSTED EBITDA⁽¹⁾⁽²⁾⁽³⁾ (In millions)

	Year Ended December 31, 2022						Non-GAAP
	GAAP	Pension & OPEB MTM (Gain) / Loss	Restructuring Costs	Acquisition-related Costs	Loss on Asset Disposal		
Net Income	\$ 238.6	\$ 35.7	\$ 6.3	\$ 2.2	\$ 4.7	\$ 287.5	
Provision for Income Taxes	75.8	10.9	1.9	0.4	1.6	90.5	
Other – net	(1.5)	(46.6)	—	—	—	(48.0)	
Interest Expense	36.4	—	(0.0)	—	—	36.4	
Interest Income	(0.8)	—	—	—	—	(0.8)	
Depreciation & Amortization	73.8	—	—	—	—	73.8	
Adjusted EBITDA	\$ 422.4	\$ —	\$ 8.2	\$ 2.6	\$ 6.2	\$ 439.4	

RECONCILIATION OF REPORTING SEGMENT ADJUSTED EBITDA⁽¹⁾⁽²⁾⁽³⁾ (In millions)

	Year Ended December 31, 2022			Adjusted EBITDA
	Operating Income (GAAP)	Non-GAAP Adjustments ⁽⁴⁾	Depreciation & Amortization	
Government Operations	\$ 336.5	\$ 2.1	\$ 48.0	\$ 386.5
Commercial Operations	\$ 27.4	\$ 7.7	\$ 18.8	\$ 53.9

RECONCILIATION OF CONSOLIDATED FREE CASH FLOW⁽¹⁾⁽²⁾⁽³⁾ (In millions)

Year Ended December 31, 2022	
Net Cash Provided By Operating Activities	\$ 244.7
Purchases of Property, Plant and Equipment	(198.3)
Free Cash Flow	\$ 46.4

- (1) Tables may not foot due to rounding.
- (2) BWXT is providing non-GAAP information regarding certain of its historical results and guidance on future earnings per share to supplement the results provided in accordance with GAAP and it should not be considered superior to, or as a substitute for, the comparable GAAP measures. BWXT believes the non-GAAP measures provide meaningful insight and transparency into the Company's operational performance and provides these measures to investors to help facilitate comparisons of operating results with prior periods and to assist them in understanding BWXT's ongoing operations.
- (3) BWXT has not included a reconciliation of provided non-GAAP guidance to the comparable GAAP measures due to the difficulty of estimating any mark-to-market adjustments for pension and post-retirement benefits, which are determined at the end of the year.
- (4) For Non-GAAP adjustment details, see reconciliation of non-GAAP operating income and earnings per share.

2021 non-GAAP reconciliations



BWXT TECHNOLOGIES, INC. RECONCILIATION OF NON-GAAP OPERATING INCOME AND EARNINGS PER SHARE⁽¹⁾⁽²⁾⁽³⁾ (In millions, except per share amounts)

Year Ended December 31, 2021

	GAAP	Pension & OPEB MTM (Gain) / Loss	Restructuring and Other Costs	Costs Associated With Early Bond Redemption	Non-GAAP
Operating Income	\$ 345.8	\$ —	\$ 3.1	\$ —	\$ 349.0
Other Income (Expense)	49.9	(39.6)	—	15.0	25.3
Income before Provision for Income Taxes	395.7	(39.6)	3.1	15.0	374.3
Provision for Income Taxes	(89.4)	9.1	(0.8)	(3.5)	(84.6)
Net Income	306.3	(30.5)	2.4	11.5	289.6
Net Income Attributable to Noncontrolling Interest	(0.4)	—	—	—	(0.4)
Net Income Attributable to BWXT	\$ 305.9	\$ (30.5)	\$ 2.4	\$ 11.5	\$ 289.2
Diluted Shares Outstanding	94.5				94.5
Diluted Earnings per Common Share	\$ 3.24	\$ (0.32)	\$ 0.03	\$ 0.12	\$ 3.06
Effective Tax Rate	22.6%				22.6%
Government Operations Operating Income	\$ 329.5	\$ —	\$ 0.2	\$ —	\$ 329.7
Commercial Operations Operating Income	\$ 35.2	\$ —	\$ 0.9	\$ —	\$ 36.2
Unallocated Corporate Operating Income	\$ (18.9)	\$ —	\$ 2.1	\$ —	\$ (16.9)

RECONCILIATION OF CONSOLIDATED ADJUSTED EBITDA⁽¹⁾⁽²⁾⁽³⁾ (In millions)

Year Ended December 31, 2021

	GAAP	Pension & OPEB MTM (Gain) / Loss	Restructuring and Other Costs	Costs Associated With Early Bond Redemption	Non-GAAP
Net Income	\$ 306.3	\$ (30.5)	\$ 2.4	\$ 11.5	\$ 289.6
Provision for Income Taxes	89.4	(9.1)	0.8	3.5	84.6
Other – net	(85.2)	39.6	—	(10.8)	(56.4)
Interest Expense	35.8	—	—	(4.2)	31.5
Interest Income	(0.4)	—	—	—	(0.4)
Depreciation & Amortization	69.1	—	—	—	69.1
Adjusted EBITDA	\$ 414.9	\$ —	\$ 3.1	\$ —	\$ 418.1

RECONCILIATION OF REPORTING SEGMENT ADJUSTED EBITDA⁽¹⁾⁽²⁾⁽³⁾ (In millions)

Year Ended December 31, 2021

	Operating Income (GAAP)	Non-GAAP Adjustments ⁽⁴⁾	Depreciation & Amortization	Adjusted EBITDA
Government Operations	\$ 329.5	\$ 0.2	\$ 42.5	\$ 372.2
Commercial Operations	\$ 35.2	\$ 0.9	\$ 19.9	\$ 56.0

RECONCILIATION OF CONSOLIDATED FREE CASH FLOW⁽¹⁾⁽²⁾⁽³⁾ (In millions)

Year Ended December 31, 2021

Net Cash Provided By Operating Activities	\$ 386.0
Purchases of Property, Plant and Equipment	(311.1)
Free Cash Flow	\$ 75.0

- (1) Tables may not foot due to rounding.
- (2) BWXT is providing non-GAAP information regarding certain of its historical results and guidance on future earnings per share to supplement the results provided in accordance with GAAP and it should not be considered superior to, or as a substitute for, the comparable GAAP measures. BWXT believes the non-GAAP measures provide meaningful insight and transparency into the Company's operational performance and provides these measures to investors to help facilitate comparisons of operating results with prior periods and to assist them in understanding BWXT's ongoing operations.
- (3) BWXT has not included a reconciliation of provided non-GAAP guidance to the comparable GAAP measures due to the difficulty of estimating any mark-to-market adjustments for pension and post-retirement benefits, which are determined at the end of the year.
- (4) For Non-GAAP adjustment details, see reconciliation of non-GAAP operating income and earnings per share.